Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen Knight

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Nursing Older People|September 1, 2017
Using technology to improve end of life careHelen Knight
European Journal of Orthodontics|July 27, 2005
Ranking facial attractivenessHelen Knight, Olly Keith
BMJ (Clinical Research Ed.)|January 26, 2023
NICE's new methods reflect society's valuesIan Watson, Helen Knight
The Lancet. Neurology|July 8, 2019
Ocrelizumab for primary progressive multiple sclerosisAmanda I Adler, Helen Knight
The Lancet. Oncology|October 4, 2016
NICE guidance on necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancerNwamaka Umeweni, Helen Knight, Gary McVeigh
The Lancet. Oncology|February 1, 2016
NICE guidance on radium-223 dichloride for hormone-relapsed prostate cancer with bone metastasesNwamaka Umeweni, Helen Knight, Gary McVeigh
The Lancet. Respiratory Medicine|January 17, 2014
NICE guidance on colistimethate sodium and tobramycin for pseudomonas lung infection in cystic fibrosisKay Nolan, Helen Knight, Peter Clark
Journal of Child Health Care : for Professionals Working with Children in the Hospital and Community|July 3, 2013
Out-of-school lives of physically disabled children and young people in the United Kingdom: a qualitative literature reviewKate Helen Knight, Lorna Porcellato, Lyvonne Tume
American Journal of Orthodontics and Dentofacial Orthopedics : Official Publication of the American Association of Orthodontists, Its Constituent Societies, and the American Board of Orthodontics|September 13, 2003
An in vivo investigation into bond failure rates with a new self-etching primer systemAnthony J Ireland, Helen Knight, Martyn Sherriff
The Lancet. Oncology|October 2, 2012
NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancerBernice Dillon, Bhash Naidoo, Helen Knight, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Nursing Older People|September 1, 2017
Using technology to improve end of life careHelen Knight
European Journal of Orthodontics|July 27, 2005
Ranking facial attractivenessHelen Knight, Olly Keith
BMJ (Clinical Research Ed.)|January 26, 2023
NICE's new methods reflect society's valuesIan Watson, Helen Knight
The Lancet. Neurology|July 8, 2019
Ocrelizumab for primary progressive multiple sclerosisAmanda I Adler, Helen Knight
The Lancet. Oncology|October 4, 2016
NICE guidance on necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancerNwamaka Umeweni, Helen Knight, Gary McVeigh
The Lancet. Oncology|February 1, 2016
NICE guidance on radium-223 dichloride for hormone-relapsed prostate cancer with bone metastasesNwamaka Umeweni, Helen Knight, Gary McVeigh
The Lancet. Respiratory Medicine|January 17, 2014
NICE guidance on colistimethate sodium and tobramycin for pseudomonas lung infection in cystic fibrosisKay Nolan, Helen Knight, Peter Clark
Journal of Child Health Care : for Professionals Working with Children in the Hospital and Community|July 3, 2013
Out-of-school lives of physically disabled children and young people in the United Kingdom: a qualitative literature reviewKate Helen Knight, Lorna Porcellato, Lyvonne Tume
American Journal of Orthodontics and Dentofacial Orthopedics : Official Publication of the American Association of Orthodontists, Its Constituent Societies, and the American Board of Orthodontics|September 13, 2003
An in vivo investigation into bond failure rates with a new self-etching primer systemAnthony J Ireland, Helen Knight, Martyn Sherriff
The Lancet. Oncology|October 2, 2012
NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancerBernice Dillon, Bhash Naidoo, Helen Knight, et al.
Pageof 2